Oxybutynin ER — Competitive Intelligence Brief

Oxybutynin ER (Oxybutynin ER) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Urology / Neurology.

marketed Anticholinergic agent Muscarinic acetylcholine receptors (M3) Urology / Neurology Small molecule

Target snapshot

Oxybutynin ER (Oxybutynin ER) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxybutynin ER TARGET	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)
Trospium Cl	Trospium Cl	Toronto Rehabilitation Institute	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3 subtype)
Atropine sulfate and epinephrine	Atropine sulfate and epinephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent and sympathomimetic amine combination	Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)
Transdermal Scopolamine	Transdermal Scopolamine	Repurposed Therapeutics, Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M1)
Active B&O suppository of belladonna	Active B&O suppository of belladonna	Edgar LeClaire, MD	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1-M5)
Topical cyclopentolate and phenylephrine	Topical cyclopentolate and phenylephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent + alpha-1 adrenergic agonist	Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine)
Slow dose preemptive Atropine	Slow dose preemptive Atropine	Abant Izzet Baysal University	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class